Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per

Related Keywords

Germany , United States , Denmark , United Kingdom , Washington , Italy , France , Spain , Greg Klassen Joele Frank , Ludovic Helfgott , Ambre Brown Morley , Frankd Lee , Daniel Muusmann Bohsen , Natalia Salomao Abrahao , David Heiberg Landsted , Jamie Moser Joele Frank , Wilkinson Brimmer Katcher , Jacob Martin Wiborg , Novo Nordisk , Holdings Inc , Linkedin , Twitter , Gdev Inc , Nasdaq , Forma Therapeutics Holdings Inc , Facebook , Drug Administration , Davis Polk Wardwell , European Commission , Centerview Partners , Exchange Commission , Youtube , Moelis Company United Kingdom , Novo Nordisk Investor Relations Department , Goodwin Procter , Forma Investor Relations Department , Forma Therapeutics , Rare Disease , Forma Therapeutic , Forma Therapeutics Board , Fast Track , Rare Pediatric Disease , Orphan Drug , Orphan Medicinal Products , European Medicines Agency , Note Regarding Forward Looking Statements , Forma Therapeutics Holdings , Tender Offer Statement , Recommendation Statement , Investor Relations Department , Brown Morley , Salomao Abrahao , Joele Frank , Muusmann Bohsen , Heiberg Landsted , Martin Wiborg Rode , Joseph Root , Novo , Nordisk , Cquire , Norma , Herapeutics , Xpand , Presence , Pickle , Fell , Disease , Mare , Flood , Disorders ,